TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05293132
Drug: Montelukast Sodium 10 mg
Normalized name: MONTELUKAST SODIUM 10 mg ORAL TABLET
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film coated tablets containing 10 mg montelukast
Study: NCT05293132
Drug: Co-Enzyme Q10
Normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules contain 210 mg Co-Enzyme Q10
Study: NCT05293132
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
Study: NCT05027646
Drug: Sancuso - Part 1
Normalized name: Sancuso
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Study: NCT05027646
Drug: Sancuso - Part 2
Normalized name: Sancuso
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Study: NCT05635734
Drug: Azeliragon 5 mg
Normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study: NCT05635734
Drug: Azeliragon 10 mg
Normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study: NCT05635734
Drug: Azeliragon 20 mg
Normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study: NCT05940844
Drug: OB-002
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
Study: NCT05178953
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
Study: NCT00000455
Drug: naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04860713
Drug: aspirin and ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
Study: NCT04906889
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
Study: NCT04906889
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
Study: NCT04908449
Drug: Rectus sheath block with bupivacaine
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectus sheath block with local anesthetic versus sham block with saline
Study: NCT05298033
Drug: Crisaborole 2 % Topical Ointment
Normalized name: crisaborole 2 % Topical Ointment
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Twice daily crisaborole 2% topical ointment
Study: NCT05298033
Drug: PF-07038124 0.01% topical ointment
DrugBank: PF-07038124 (DB19143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily PF-07038124 0.01% topical ointment
Study: NCT06663358
Drug: Pegunigalsidase-alfa
Normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion under conditions of routine clinical care
Study: NCT05095857
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
Study: NCT00000849
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04991506
Drug: ES102
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
Study: NCT04962152
Drug: Nalbuphine Sebacate or Sesame oil (placebo)
Normalized name: Sesame Oil
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound-guided intramuscular injection after the induction of anesthesia immediately
Study: NCT04714073
Drug: BI 706321
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 706321
Study: NCT04714073
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole
Study: NCT06535529
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
Study: NCT06535529
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
Study: NCT05756673
Drug: Colgate Cavity Protection Toothpaste
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study: NCT00000650
Drug: Ditiocarb sodium
Normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06182072
Drug: Gemcitabine, nab paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
Study: NCT04933682
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT04933682
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule.
Study: NCT04695847
Drug: M1231
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study: NCT04695847
Drug: M1231
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study: NCT05984381
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone 100 mg/day
Study: NCT06671821
Drug: HRS-7535
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7535
Study: NCT06217536
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT06184269
Drug: BR1017-1A
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06184269
Drug: BR1017-1B
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06681623
Drug: Ublituximab
Normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ublituximab
Study: NCT06684626
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
Study: NCT06684626
Drug: Levofloxacin 500mg
Normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment typically involves fluoroquinolones alone, such as levofloxacin.
Study: NCT06687876
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.
Study: NCT06691217
Drug: CANAKINUMAB (ILARIS®)
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
Study: NCT06691217
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
Study: NCT06693128
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg
Study: NCT06693128
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250mg
Study: NCT06693128
Drug: S-1, Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S-1, Oxaliplatin, q3w
Study: NCT06512363
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
Study: NCT06512363
Drug: Ramelteon placebo
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Study: NCT06697184
Drug: Sonrotoclax
Normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06697184
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT06719791
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².
Study: NCT05317819
Drug: ADI-PEG20
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hepatocellular carcinoma
Study: NCT06721013
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04454203
Drug: Mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.
Study: NCT04454203
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An infiltration of saline superomedially to the femoral artery via perineural catheter.
Study: NCT06719700
Drug: Angio-immuno kinase inhibitor
Normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
Study: NCT06719700
Drug: Consolidation Therapy with Toripalimab and Surufatinib
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
Study: NCT06720259
Drug: Oxantel Pamoate
Normalized name: OXANTEL PAMOATE
DrugBank: Oxantel (DB13670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 250 mg oxantel pamoate
Study: NCT06720259
Drug: Mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets containing 500 mg mebendazole
Study: NCT06719856
Drug: 18-FDG
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study: NCT04885491
Drug: Sodium chloride (placebo)
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
Study: NCT06624644
Drug: Chemotherapy (dacarbazine or temozolomide)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (dacarbazine, temozolomide)
Study: NCT04875039
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
Study: NCT04875039
Drug: Dexmedetomidine-Dexamethasone
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
Study: NCT04870112
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-L1 antibody
Study: NCT04870112
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT04870112
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT04870112
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT05640713
Drug: Fludarabine Pill
Normalized name: fludarabine Pill
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is used for lymphodepletion.
Study: NCT05640713
Drug: VP-16 Protocol
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VP-16 is used for lymphodepletion.
Study: NCT05679687
Drug: Treatment
Normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
Study: NCT05008913
Drug: [14C]Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
Study: NCT05219721
Drug: CAR-T (CAR-GPRC5D)
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain. The amplification and persistence of CAR T are enhanced by 4-1BB costimulation signal.
Study: NCT06031480
Drug: Anlotinib and TQB2450
Normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent.
Study: NCT06310304
Drug: Ruxolitinib IR
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT06310304
Drug: Ruxolitinib XR
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT05281601
Drug: AZD7442
Normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion.
Study: NCT04752332
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT00002452
Drug: L-756423
Normalized name: L
DrugBank: L-756423 (DB02009)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002452
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00086710
Drug: Fuzeon
Normalized name: Fuzeon
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06462586
Drug: Lumateperone
Normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone 42 mg capsules administered orally, once daily
Study: NCT05896813
Drug: CMOP+Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
Study: NCT03496610
Drug: Liposomal Bupivicaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
Study: NCT03766750
Drug: Tradjenta
Normalized name: Tradjenta
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 coated tablet, oral, once a day.
Study: NCT03766750
Drug: Forxiga
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 coated tablet, oral, once a day.
Study: NCT05057273
Drug: BT-11
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily tablet
Study: NCT05057273
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic
Study: NCT05874401
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive intravenous trilaciclib infusion
Study: NCT05874401
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive intravenous topotecan infusion
Study: NCT06472258
Drug: IV Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.